Van Andel Institute: Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease, following publication of research findings today in the journal Science Translational Medicine.

Read more: Van Andel Institute: Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year